Tissue factor: beyond coagulation in the cardiovascular system

被引:44
作者
Breitenstein, Alexander [1 ,2 ,3 ]
Camici, Giovanni G. [1 ,2 ]
Tanner, Felix C. [1 ,2 ,3 ]
机构
[1] Univ Zurich, Inst Physiol, Zurich, Switzerland
[2] Univ Zurich, Ctr Integrat Human Physiol, Zurich, Switzerland
[3] Univ Zurich Hosp, Cardiovasc Ctr, CH-8091 Zurich, Switzerland
基金
瑞士国家科学基金会;
关键词
cardiovascular disease; coagulation cascade; endothelial cell; fibrin; risk factor; tissue factor; vascular smooth muscle cell; FACTOR PATHWAY INHIBITOR; SMOOTH-MUSCLE-CELLS; C-REACTIVE PROTEIN; HUMAN ENDOTHELIAL-CELLS; FACTOR MESSENGER-RNA; FACTOR-POSITIVE MICROPARTICLES; HUMAN ATHEROSCLEROTIC PLAQUES; FACTOR PROCOAGULANT ACTIVITY; PERIPHERAL-BLOOD MONOCYTES; FACTOR EXPRESSION;
D O I
10.1042/CS20080622
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
TF (tissue factor) is the main trigger of the coagulation cascade; by binding Factor VIIa it activates Factor IX and Factor X, thereby resulting in fibrin formation. Various stimuli, such as cytokines, growth factors and biogenic amines, induce TF expression and activity in vascular cells. Downstream targets of these mediators include diverse signalling molecules such as MAPKs (mitogen-activated protein kinases), PI3K (phosphoinositide 3-kinase) and PKC (protein kinase C). In addition, TF can be detected in the bloodstream, known as circulating or blood-borne TF. Many cardiovascular risk factors, such as hypertension, diabetes, dyslipidaemia and smoking, are associated with increased expression of TF, Furthermore, in patients presenting with acute coronary syndromes, elevated levels of circulating TF are found. Apart from its role in thrombosis, TF has pro-atherogenic properties, as it is involved in neointima formation by inducing vascular smooth muscle cell migration. As inhibition of TF action appears to be an attractive target for the treatment of cardiovascular disease, therapeutic strategies are under investigation to specifically interfere with the action of TF or, alternatively, promote the effects of TFPI (TF pathway inhibitor).
引用
收藏
页码:159 / 172
页数:14
相关论文
共 171 条
[1]   Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor [J].
Abe, K ;
Shoji, M ;
Chen, J ;
Bierhaus, A ;
Danave, I ;
Micko, C ;
Casper, K ;
Dillehay, DL ;
Nawroth, PP ;
Rickles, FR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (15) :8663-8668
[2]   Disulfide isomerization switches tissue factor from coagulation to cell signaling [J].
Ahamed, Jasimuddin ;
Versteeg, Henri H. ;
Kerver, Marjolein ;
Chen, Vivien M. ;
Mueller, Barbara M. ;
Hogg, Philip J. ;
Ruf, Wolfram .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (38) :13932-13937
[3]   DIFFERENTIAL EXPRESSION OF TISSUE FACTOR PROTEIN IN DIRECTIONAL ATHERECTOMY SPECIMENS FROM PATIENTS WITH STABLE AND UNSTABLE CORONARY SYNDROMES [J].
ANNEX, BH ;
DENNING, SM ;
CHANNON, KM ;
SKETCH, MH ;
STACK, RS ;
MORRISSEY, JH ;
PETERS, KG .
CIRCULATION, 1995, 91 (03) :619-622
[4]   Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia [J].
Aras, O ;
Shet, A ;
Bach, RR ;
Hysjulien, JL ;
Slungaard, A ;
Hebbel, RP ;
Escolar, G ;
Jilma, B ;
Key, NS .
BLOOD, 2004, 103 (12) :4545-4553
[5]   Tissue-factor antigen and activity in human coronary atherosclerotic plaques [J].
Ardissino, D ;
Merlini, PA ;
Ariens, R ;
Coppola, R ;
Bramucci, E ;
Mannucci, PM .
LANCET, 1997, 349 (9054) :769-771
[6]   Tissue factor encryption [J].
Bach, RR .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (03) :456-461
[7]   Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques - Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions [J].
Badimon, JJ ;
Lettino, M ;
Toschi, V ;
Fuster, V ;
Berrozpe, M ;
Chesebro, JH ;
Badimon, L .
CIRCULATION, 1999, 99 (14) :1780-1787
[8]   Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor κB, and Egr-1 [J].
Bavendiek, U ;
Libby, P ;
Kilbride, M ;
Reynolds, R ;
Mackman, N ;
Schönbeck, U .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (28) :25032-25039
[10]   Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation [J].
Bea, F ;
Blessing, E ;
Shelley, MI ;
Shultz, JM ;
Rosenfeld, ME .
ATHEROSCLEROSIS, 2003, 167 (02) :187-194